Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-812-5 | CAS number: 110-88-3
Endpoint summary
Administrative data
Description of key information
LD50 oral >3200 mg/kg bw (no mortalities and no severe signs of toxicity were observed up to the highest dose tested)
LC50 inhal. >39.2 mg/l (no mortality and only mild signs of toxicity at maximally achievable vapor concentration)
LD50 dermal >3980 mg/kg bw (no clinical symptoms of toxicity)
Key value for chemical safety assessment
Additional information
Acute oral:
According to an old but well performed industrial hygiene test no classification for acute oral toxicity is indicated (BASF AG, 1968). In rats no mortalities and no severe signs of toxicity were observed up to the highest dose tested (3200 mg/kg bw).
This data was confirmed by additional incompletely reported studies (LD50 >5000 mg/kg bw, Celanese 1962; LD50 approx. 8500 mg/kg bw, Czajkowska et al. 1985).
Acute inhalation:
No mortality and only mild signs of toxicity (secretion, respiratory distress, poor condition and mild loss of body weight) were observed at the maximally achievable vapor concentration of 39.2 mg/l (Bio/Dynamics Inc., 1986). The whole body of rats was exposed and the test atmosphere was analytically characterized.
(The calculated saturated vapor concentration is 0.0412 x 90 g/mol x 11hPa = 40.1 mg/l.)
Accordingly, further inhalation risk tests did not indicate signs of toxicity following exposure to vapor atmospheres of 26 mg/l (Czajkowska et al., 1987) or 22 mg/l air (BASF AG, 1968). No analysis of the test atmosphere was performed in these assays.
Based on this information no classification is warranted since no significant signs of toxicity were observed when tested above the limit dose for GHS Cat.4 (20mg/l for vapor).
Acute toxicity dermal:
No clinical symptoms of toxicity were observed following single dermal application of 3980 mg/kg bw trioxane for 24 h to male rats (IHFA, 1962). Slight to moderate skin irritation (erythema) was observed but no classification is indicated.
Similarly no acute dermal toxicity in rats (LD50 >15000mg/kg bw) was reported in an incompletely reported czech study (Czajkowska et al., 1987).
Justification for classification or non-classification
No mortality or significant signs of toxicity were observed at the guidance values for all routes of exposure according to Directive 67/548/EEC or Directive 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
